Ethypharm SAS

Based in France, Ethypharm SAS specializes in the development and production of essential medicines, focusing on Central Nervous System disorders and Hospital Injectables to address critical healthcare needs. Founded in 1977, Ethypharm SAS is located in Saint-Cloud, France, and operates in the pharmaceutical industry. The firm has undergone strategic changes, including its acquisition by PAI Partners alongside management in June 2016. The company's leadership includes Bertrand Deluard, Denis Delval, and Roland Krock.

Ethypharm is a mid-size international specialty pharmaceutical company that focuses on manufacturing and providing essential medicines primarily in the areas of Central Nervous System (CNS) disorders, specifically severe pain management and addiction, as well as Hospital Injectables. The company’s product offerings include analgesics such as Nefopam HCl, an injectable solution for moderate to severe pain, and Recivit® (fentanyl), used for managing severe pain in clinical settings. These products are designed to address critical healthcare needs, particularly in environments such as hospitals where effective pain management and addiction treatment are essential. Ethypharm serves a diverse client base, including healthcare professionals, hospitals, and pharmaceutical distributors in markets such as Spain and France, where these products have been strategically introduced to meet local therapeutic demands.

In the most recent year, Ethypharm reported a revenue of USD 145. 81 mn and an EBITDA of USD 14. 79 mn. The company generates revenue through a combination of direct sales to healthcare institutions and partnerships with pharmaceutical distributors.

The transaction structure typically involves B2B relationships, where hospitals and healthcare providers procure medications through negotiated contracts or licensing agreements. For instance, the licensing agreement for Nefopam HCl in Spain exemplifies the firm’s approach to expanding its product reach through strategic partnerships. Revenue streams are further supported by the distribution of trademarked products like Recivit®, enhancing the company's presence in the European pharmaceutical market. Pricing structures are determined based on the competitive landscape and therapeutic value of the company's offerings, ensuring that their essential medicines remain accessible to end users while meeting regulatory requirements across different regions.

Ethypharm is focused on advancing its product pipeline and expanding into new markets. The company is planning to launch several new products designed for severe pain management and addiction treatment within the next couple of years. Additionally, Ethypharm aims to penetrate further into the Spanish and broader European markets, leveraging its existing distribution channels. The recent acquisition by PAI Partners will support these initiatives by providing necessary capital for product development and market expansion.